Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Peptide hormone ELABELA promotes rat bone marrow-derived mesenchymal stem cell proliferation and migration by manipulating the cell cycle through the PI3K/AKT pathway under the hypoxia and ischemia microenvironment

Fig. 4

ELA activates the PI3K/AKT signaling pathway in RAT BM-MSCs under H/I conditions for 24 h. The treatment time of ELA (at a concentration of 5 μM) was 12 h prior to H/I injury. A The representative blots showed the protein level of total-AKT and p-AKT (Ser 473) in RAT BM-MSCs. B The quantitative data were calculated with the ratio of p-AKT and t-AKT. *P < 0.05. ELA, ELABELA; RAT BM-MSCs, Rat bone marrow-derived mesenchymal stem cells; H/I, hypoxic-ischemic; LY, LY294002; t-AKT, total-AKT; p-AKT, phosphorated-AKT

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512